About Nvron Life Science Limited
Data last updated: 09 January 2026
Nvron Life Science Limited is a public limited company based in Coimbatore, Tamil Nadu, India, recognised as a startup by DPIIT. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 08 July 2015, the company has been in operation for over 11 years.
Registered with ROC Coimbatore under CIN U33110TZ2015PLC021561.
Capital: an authorised share capital of ₹1 Cr and a paid-up capital of ₹43.65 Lakh. It is led by directors including Radhajanani Sukumar and Jegatheesan Jayaraman.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: V.M. Towers B2 Selvakumarasamy Gardens Theivanayagi Nagar Ganapathy Post, Coimbatore, Tamil Nadu, India – 641006.
As per the financials filed for FY 2025, the company reported a revenue of ₹4.4 Cr, a growth of 61% compared to the previous year.
The company has a workforce of approximately 4 employees as per the latest available data. Its group structure includes 1 subsidiary.
The company is associated with 3 brands - Nvron Life Science, Natural Infusions, Prema Hospital. As per MCA filings, the company has open charges of ₹25 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website nvronlifescience.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressV.M. Towers B2 Selvakumarasamy Gardens Theivanayagi Nagar Ganapathy Post, Coimbatore, Tamil Nadu, India – 641006
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Nvron Life Science Limited
Nvron Life Science Limited operates multiple associated brands including Nvron Life Science, Natural Infusions, and Prema Hospital. These brands represent Nvron Life Science Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Provides contract manufacturing services for finished dosage forms in pharmaceuticals. | nvronlifescience.com | |
| Offers natural haircare products like serums and shampoos for everyday use. | naturalinfusions.in | |
| Healthcare services encompassing emergency care, surgical procedures, and specialized treatments in Coimbatore. | premahospital.com |
Competitors & Alternatives of Nvron Life Science Limited
Brands and companies operating in the same space as Nvron Life Science Limited include Jubilant Life Sciences, Akums, Nectar Lifesciences and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Jubilant Life Sciences
|
Company offering a suite of R&D and manufacturing services for small molecules and generics | Noida, India, India | 1978 |
Akums
|
CDMO focusing on spectrum of dosage forms and therapeutic segments | Delhi, India, India | 2004 |
Nectar Lifesciences
|
Cephalosporin APIs and generic formulations are manufactured. | Chandigarh, India, India | 1995 |
Fix My Curls
|
Provider of hair care products formulated for curly, wavy, and coily hair | Gurugram, India, India | 2019 |
Windlas
|
Biopharma regulatory affairs, quality control, and strategy services are provided. | Gurugram, India, India | 2001 |
Unither
|
Contract development and manufacturing organization for proprietary and generic drugs | Paris, France, France | 1993 |
Moxie Beauty
|
Online brand offering hair care products | Delhi, India, India | 2022 |
Recipharm
|
Pharmaceutical development and manufacturing services are offered contractually. | Jordbro, Sweden, Sweden | 1995 |
CoreRx
|
CDMO with a focus on early phase drug product development | Clearwater, United States, United States | 2006 |
MedPharm
|
Topical and inhaled drug delivery formulations are developed and manufactured. | Guildford, United Kingdom, United Kingdom | 1998 |
Business Activity of Nvron Life Science Limited
Nvron Life Science Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Nvron Life Science Limited
Nvron Life Science Limited is audited by KARTHIKEYAN & JAYARAM for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| KARTHIKEYAN & JAYARAM | blur-value | blur-value | blur-value |
Board of Directors of Nvron Life Science Limited
Nvron Life Science Limited is currently managed by 4 directors, with 4 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Radhajanani Sukumar
Also directs:
Natural Infusions Private Limited, Veerix Biotech Private Limited
|
Director | 05 Aug 2019 | 6 Years 11 Months | Current |
| Jegatheesan Jayaraman | Director | 05 Aug 2019 | 6 Years 11 Months | Current |
|
Subash Chandra Boss Santhosh Kumar
Also directs:
Natural Infusions Private Limited, Veerix Biotech Private Limited
|
Director | 08 Jul 2015 | 11 Years 0 Months | Current |
| Girija Sukumar | Additional Director | 22 Aug 2025 | 0 Years 10 Months | Current |
Financials of Nvron Life Science Limited FY 2024 filings available
Nvron Life Science Limited reported revenue of ₹4.4 Cr (up 61% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Nvron Life Science Limited
As of FY 2023, Nvron Life Science Limited's shareholding pattern shows 95.40% by promoters, 4.60% by public shareholders. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Nvron Life Science Limited
Nvron Life Science Limited has 1 subsidiary company. This group structure data is as of FY 2023. The corporate group structure reflects Nvron Life Science Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Nvron Health Care Private Limited | U24299TZ2016PTC027712 |
**.**%
|
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Nvron Life Science Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Feb 2025 | Others | ₹25 Lakh | Open |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Nvron Life Science Limited
Nvron Life Science Limited has a workforce of 4 employees as of Apr 07, 2024.
Employee Count & EPFO Data of Nvron Life Science Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Nvron Life Science Limited
GSTIN & GST Filing Data of Nvron Life Science Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Nvron Life Science Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Nvron Life Science Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Nvron Life Science Limited
MSME Payment Delays by Nvron Life Science Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Nvron Life Science Limited
Subsidiaries & Group Companies of Nvron Life Science Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Nvron Life Science Limited with ownership details.
MCA Filings & Documents of Nvron Life Science Limited
MCA Filings & Documents of Nvron Life Science Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Nvron Life Science Limited
Frequently Asked Questions about Nvron Life Science Limited
Nvron Life Science Limited is an active public limited company in the pharma sector based in Coimbatore, Tamil Nadu, India. It was incorporated on 08 July 2015 (11+ years old) and is registered under CIN U33110TZ2015PLC021561. The company has 4 employees.
Nvron Life Science Limited reported revenue of ₹4.4 Cr for FY 2025 (up 61.00% YoY).
The current directors of Nvron Life Science Limited are:
The primary industry of Nvron Life Science Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes, Nvron Life Science Limited is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).
Nvron Life Science Limited can be reached at the registered office: V.M. Towers B2 Selvakumarasamy Gardens Theivanayagi Nagar Ganapathy Post, Coimbatore, Tamil Nadu, India – 641006, or through the website nvronlifescience.com.